Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUBE00 in Solid Tumors
NCT07030959Phase 1Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of AUBE00 in solid tumor (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Adverse Events up to 55 months, Changes in Vital Signs up to 55 months and 8 more. Started Jun 2025; status: recruiting.
02
Drugs
AUBE00
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07030959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030959.